NYSE$HCA

HCA Holdings Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

HCA Healthcare's financial performance in Q4 2022 showed increased revenues and net income compared to the same period last year, with same facility admissions and equivalent admissions also increasing.

HCA Healthcare reported a strong fourth quarter in 2022, with revenues totaling $15.497 billion and net income attributable to HCA Healthcare, Inc. reaching $2.081 billion, or $7.28 per diluted share. The company's performance benefited from increased same facility admissions and equivalent admissions.

  • Revenues totaled $15.497 billion.
  • Net income attributable to HCA Healthcare, Inc. totaled $2.081 billion, or $7.28 per diluted share.
  • Adjusted EBITDA totaled $3.179 billion.
  • Cash flows from operating activities totaled $2.527 billion.
  • Same facility admissions increased 2.9 percent while same facility equivalent admissions increased 5.4 percent

Headline financials

Total Revenue

$15.5B

Previous: $15.1B+2.9%
EPS (adj)

$4.64

Previous: $4.42+5.0%
Admissions

530.3K

Previous: 514.7K+3.0%
Number of Hospitals

182

Previous: 182+0.0%
Licensed Beds at End of Period

49.3K

Previous: 48.8K+1.0%
Occupancy

72.0%

Previous: 70.2%+2.6%
Capital Expenditures

$1.32B

Previous: $1.19B+11.0%
Free Cash Flow

$1.2B

Previous: $1.25B-3.8%
Net Income

$2.08B

Previous: $2.01B+3.8%
Operating Income

$3.3B

Previous: $2.59B+27.7%
Gross Profit

$13.1B

Previous: $12.7B+3.3%
Cash & Equivalents

$908M

Previous: $1.45B-37.4%
Total Assets

$52.4B

Previous: $50.7B+3.3%
Stock-Based Comp

$83M

Previous: $99M-16.2%

Revenue & EPS history

HCA · Revenue · Quarterly

$15.5B

Q4 2022+2.9%vs Q4 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

The Company issued the following estimated guidance for 2023:

Tailwinds

  • Revenues $61.5 to $63.5 billion
  • Net Income Attributable to HCA Healthcare, Inc. $4.525 to $4.895 billion
  • Adjusted EBITDA $11.8 to $12.4 billion
  • EPS (diluted) $16.40 to $17.60 per diluted share

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.9%

Avg return

30 days after

47%

31 / 66 earnings

Positive

+16.1%

Q2 2020

Best reaction

-21.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.2%-8.3%-16.8%
Q4 2025+6.2%+3.4%+11.3%
Q3 2025+1.5%+6.4%+11.6%
Q2 2025+0.8%+3.1%+3.8%
Q1 2025-4.0%+1.1%+10.3%
Q4 2024-3.8%+0.7%-2.7%
Q3 2024-10.6%-9.5%-18.5%
Q2 2024+5.7%+9.0%+17.7%
Q1 2024-0.9%-1.5%+1.5%
Q4 2023+6.3%+7.9%+8.7%
Q3 2023-6.5%-6.5%+5.0%
Q2 2023-3.2%-2.9%-3.2%
Q1 2023+5.7%+2.7%+4.3%
Q4 2022-0.6%+2.6%-2.2%
Q3 2022+0.8%+4.3%+10.3%
Q2 2022+9.6%+12.9%+18.6%
Q1 2022-21.9%-21.2%-24.0%
Q4 2021-1.4%-1.1%+5.5%
Q3 2021-7.0%-5.6%-8.1%
Q2 2021+14.5%+14.2%+13.3%
Q1 2021+2.5%+0.7%+4.5%
Q4 2020+3.7%+5.9%+5.6%
Q3 2020-4.4%-9.3%+12.5%
Q2 2020+16.1%+14.6%+21.2%
Q1 2020-5.4%-2.4%-2.2%
Q4 2019+2.6%-2.0%-10.1%
Q3 2019+6.2%+5.3%+10.3%
Q2 2019-8.7%-13.0%-17.4%
Q1 2019-1.1%+0.2%-2.3%
Q4 2018+5.6%+6.1%+5.5%
Q3 2018+3.5%+4.2%+12.0%
Q2 2018+14.9%+14.7%+21.4%
Q1 2018+2.1%+1.9%+7.7%
Q4 2017+3.6%+2.1%+1.9%
Q3 2017+0.9%+0.3%+11.6%
Q2 2017-5.2%-6.6%-7.9%
Q1 2017-1.2%-0.4%-0.1%
Q4 2016+3.4%+5.7%+10.2%
Q3 2016-2.1%-4.5%-9.6%
Q2 2016-1.1%-3.8%-4.8%
Q1 2016-1.7%
Q4 2015+3.1%
Q3 2015-0.1%
Q2 2015-2.8%
Q1 2015-1.2%
Q4 2014-1.7%
Q3 2014-2.1%
Q2 2014+4.1%
Q1 2014-1.2%
Q4 2013-1.0%
Q3 2013-5.1%
Q2 2013+0.1%
Q1 2013+3.8%
Q4 2012-1.1%
Q3 2012+8.0%
Q2 2012+1.1%
Q1 2012-1.1%
Q4 2009+3.5%
Q4 2011+3.5%
Q3 2011+2.6%
Q3 2010+2.6%
Q2 2011-20.6%
Q2 2010-20.6%
Q1 2011-0.2%
Q1 2010-0.2%
Q4 2010-0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro